Edesa Biotech, Inc.

( )
EDSA After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
PFEPfizer Inc. -1.10%45.180.9%$1266.01m
JNJJohnson & Johnson -0.56%173.420.7%$1039.49m
AZNAstraZeneca Plc -0.61%57.311.0%$963.13m
LLYEli Lilly & Co. 2.56%262.531.1%$683.11m
ABBVAbbVie, Inc. -1.02%115.071.9%$660.94m
MRKMerck & Co., Inc. -1.24%75.460.7%$655.76m
BMYBristol-Myers Squibb Co. -1.24%68.451.0%$576.62m
GSKGlaxoSmithKline Plc -0.34%40.500.2%$160.71m
NRXPNRX Pharmaceuticals, Inc. -8.49%14.660.0%$158.90m
NVSNovartis AG -1.22%91.580.2%$158.06m
BYSIBeyondSpring, Inc. 176.01%26.580.0%$104.18m
NVONovo Nordisk A/S 5.49%98.240.1%$101.33m
RGENRepligen Corp. 1.41%252.596.8%$97.77m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. 3.72%123.200.0%$87.25m
VTRSViatris, Inc. -3.03%13.760.0%$86.16m

Company Profile

Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquiring, developing and commercializing clinical stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. The company product candidate, EB01 is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis (ACD), a common, potentially debilitating condition and occupational illness. EB01 employs a novel, non-steroidal mechanism of action and in two clinical studies has demonstrated statistically significant improvement of multiple symptoms in ACD patients. Edesa Biotech was founded on June 12, 2007 and is headquartered in Markham, Canada.